Howard Liang, Ph.D., CFO and Chief Strategy Officer of BeiGene, obtained his M.B.A. and Ph.D. in Biochemistry and Molecular Biology from The University of Chicago, and his B.S. in Chemistry from Peking University. Prior to joining BeiGene, Dr. Liang spent 10 years at Leerink Partners, where he was a Managing Director and Head of Biotechnology Equity Research. Dr. Liang also held positions including senior biotechnology analyst at AG Edwards and JMP Securities, and associate analyst at Prudential Securities, where he started his career on Wall street. Dr. Liang was granted the “Best of the Street” in Biotechnology & Pharmaceuticals and in Biotechnology by Wall Street Journal, Bloomberg Markets Top US Analysts in Biotechnology, and Institutional Investor All-America Research Team in Biotechnology / Mid- & Small-Cap. Before joining Wall Street, Dr. Liang spent eight years at Abbott Laboratories, where he was a senior scientist and a member of one of the industry’s leading structure-based drug discovery teams. During his career as a scientist, Dr. Liang authored a review and 13 papers including 6 in Nature, Science, and Proceedings of the National Academy of Sciences.